← MannKind Corporation (MNKD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MannKind Corporation (MNKD)
Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
15
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
MannKind Corporation (MNKD) is a ~$1.25B market-cap specialty biopharmaceutical company focused on diabetes and pulmonary arterial hypertension, best known for its inhaled insulin platform (Afrezza/Technosphere). The company recently received an FDA approval on 2026-06-28 and carries a meaningful September 2026 PDUFA date (importance 8/10) as the next binary catalyst, against a backdrop of rapidly accelerating revenues ($75M in 2021 to $349M in 2025) but persistent net debt of ~$266M.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 2 · Basal insulinimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Technosphere Insulin Inhalation Powder | Phase 2 | Diabetes Type 2 |
| Active comparator | Phase 3 | Diabetes, Type I |
| Technosphere/Insulin | Phase 2 | Diabetes Mellitus, Type 2 |
| Technosphere Insulin | Phase 3 | Type 2 Diabetes Mellitus |
| 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) | Phase 3 | Diabetes Type 2 |
| Actrapid | Phase 2 | Type 2 Diabetes Mellitus |
| MKC1106-MT | Phase 2 | Melanoma (Skin) |
| Afrezza | Phase 3 | Diabetes Mellitus, Type 1 |
| Metformin & Secretagogues | Phase 3 | Diabetes Mellitus, Type 2 |
| Technosphere® Insulin with MedTone C Inhaler | Phase 3 | Type 1 Diabetes Mellitus |
| Usual Care | Phase 3 | Diabetes, Type 1 |
| Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler | Phase 2 | Type 2 Diabetes Mellitus |
| Technosphere® Insulin | Phase 3 | Type 2 Diabetes |
| Technosphere® Insulin Inhalation Powder | Phase 2 | Diabetes Mellitus: Type 1 |
| Basal insulin | Phase 2 | Type 1 Diabetes Mellitus |
Price & technical context
3-month
-12.6%
6-month
+55.5%
12-month
-26.4%
52-wk range
$2.28–$6.21
vs 50-day MA
+2.3%
vs 200-day MA
-1.0%
Realized vol
74.1%
Max drawdown
-69.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MNKD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 15 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.